{Reference Type}: Case Reports
{Title}: Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline.
{Author}: Pedersen AA;Fløe A;Løkke A;Hilberg O;
{Journal}: BMJ Case Rep
{Volume}: 16
{Issue}: 12
{Year}: 2023 Dec 16
暂无{DOI}: 10.1136/bcr-2023-255383
{Abstract}: Pulmonary disease caused by Mycobacterium abscessus is difficult to treat, as there is currently no reliable evidence-based treatment. Treatment is long, complex and has many side effects. In this case, we report a patient with treatment-refractory pulmonary M abscessus disease, treated with inhaled tigecycline. Treatment with inhaled tigecycline lasted 15 months with comparably limited side effects. There were no positive mycobacterial cultures in the follow-up period of 2 years. Inhaled tigecycline is an option in the treatment of pulmonary M. abscessus when first-line treatment fails. Additional research should investigate this further.